Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 4760401 trials

ORGANOIDSCIENCES LTD.

Official website

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

As of 2026-10-10, ORGANOIDSCIENCES LTD. has 34 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

ORGANOIDSCIENCES LTD. was founded in October 2018 and listed on the KOSDAQ market in May 2025 as an organoid-based biotech company. Its core business spans the intestinal organoid therapeutic ATORM-C built on the ATORM regenerative-therapeutics platform, the new-material evaluation solution ODISEI, and the research reagent brand organoEZ. The tumor organoid evaluation solution ODISEI-ONC was commercialized in 2020, ODISEI uses more than 20 types of organ-specific organoids, and the company has also expanded into immuno-oncology precision medicine and cell/tissue-engineering CDMO services.

Products & technology

  • ATORM-CSingle local-administration therapeutic derived from adult stem cell-based intestinal organoids for refractory intestinal ulcers (IBD, Behcet's enteritis, radiation proctitis, stercoral ulcer)
  • ODISEIOrganoid-based new-material evaluation solution predicting human-body effects of new materials for drugs, food, and cosmetics, using more than 20 types of organ-specific organoids (tumor, virus, intestine, skin, etc.)
  • organoEZCustomized organoid research reagent product line leveraging the company's culture know-how

Clinical trials

data.go.kr

1 MFDS clinical trial authorisations · 2026 (Phase 1 1)

  • Phase 1ATORM-C2026-03-13

    2 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

ATORM-C · 난치성 장궤양(염증성 장질환(IBD), 베체트 장염, 방사선 직장염, 숙변성 궤양 등) · 첨단재생의료 임상연구(2022년 보건복지부 승인, 진행중) · In December 2025, filed an IND application with the MFDS for a Phase 1 clinical trial in patients with Crohn's disease accompanied by colonic ulcers

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 24 more publications

Patents

KIPRIS · applicant-matched
Show 53 more patents

AI reads

MAA server logs · IP-verified
226
Times AI engines pulled ORGANOIDSCIENCES LTD.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

4
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

222
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

23
live 1
Last 7 days
177
live 4
Last 30 days
226
live 4
All time
  • OpenAIChatGPT-Userlive4
  • OpenAIOAI-SearchBot180
  • GoogleGoogleOther34
  • PerplexityPerplexityBot5
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for ORGANOIDSCIENCES LTD. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

MEDIPOSTCO.,LTD.83

Medipost, founded in 2000 and KOSDAQ-listed in 2005, specializes in cord blood banking and stem cell therapeutics.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition